Predicting acute side effects of stimulant medication in pediatric attention deficit/hyperactivity disorder: Data from quantitative electroencephalography, event-related potentials, and a continuous-performance test

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1301-1309

  Ogrim, Geir ^a,b,c   Hestad, Knut A ^c,d   Brunner, Jan Ferenc ^c,e   Kropotov, Juri ^c,f,g  

^a Østfold Hospital Trust   (Norway)

^b National Centre for AD/HD   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d INNLANDET HOSPITAL TRUST   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f Institute of the Human Brain Russian Academy of Sciences   (Russian Federation)

^g ANDRZEJ FRYCZ MODRZEWSKI KRAKOW UNIVERSITY   (Poland)

Author keywords

ADHD; ERP; Go no go test; QEEG; Side effects; Stimulants

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

ADOLESCENT; AGE; ANXIETY; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; BEHAVIOR; CHILD; COGNITION; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRUG DOSE TITRATION; DYSPHORIA; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FEMALE; GENDER; HEADACHE; HUMAN; IMAGING SYSTEM; INSOMNIA; INTERVIEW; IRRITABILITY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; PERCEPTION; PREDICTION; PSYCHOLOGIST; PSYCHOSIS; QUANTITATIVE DIAGNOSIS; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; VISUAL CONTINUOUS PERFORMANCE TEST;

EID: 84884403089     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S49611     Document Type: Article

References (55)

1. [No authors listed]. Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105(5):1158-1170.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision. Washington: American Psychiatric Association; 2000.
3. Polanczyk G, Jensen P. Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update. Child Adolesc Psychiatr Clin N Am. 2008;17(2):245-260.
4. Gillberg C, Gillberg IC, Rasmussen P, et al. Co-existing disorders in ADHD-implications for diagnosis and intervention. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I80-I92.
5. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4): 409-432.
6. Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 3rd ed. New York: Guilford; 2006.
7. Zeiner P, Bryhn G, Bjercke C, Truyen K, Strand G. Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatr. 1999;88(3):298-303.
8. Tannock R, Schachar RJ, Carr RP, Chajczyk D, Logan GD. Effects of methylphenidate on inhibitory control in hyperactive children. J Abnorm Child Psychol. 1989;17(5):473-491.
9. Schweitzer JB, Lee DO, Hanford RB, et al. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol Psychiatry. 2004;56(8):597-606.
10. Biederman J, Petty CR, Doyle AE, et al. Stability of executive function deficits in girls with ADHD: a prospective longitudinal followup study into adolescence. Dev Neuropsychol. 2008;33(1):44-61.
11. Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2006;30(8): 1225-1245.
12. Atkinson M, Hollis C. NICE guideline: attention deficit hyperactivity disorder. Arch Dis Child Educ Pract Ed. 2010;95(1):24-27.
13. Taylor E, Döpfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-I30.
14. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15(8):476-495.
15. Solanto M, Newcorn J, Vail L, Gilbert S, Ivanov I, Lara R. Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(6):663-671.
16. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ. Placebo-controlled evaluation of ritalin side effects. Pediatrics. 1993;91(6):1101-1106.
17. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2):184-192.
18. Rapport MD, Kofler MJ, Coiro MM, Raiker JS, Sarver DE, Alderson RM. Unexpected effects of methylphenidate in attention-deficit/hyperactivity disorder reflect decreases in core/secondary symptoms and physical complaints common to all children. J Child Adolesc Psychopharmacol. 2008;18(3):237-247.
19. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100(4):662-666.
20. Sonuga-Barke EJ, Coghill D, Wigal T, DeBacker M, Swanson J. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol. 2009;19(6):683-690.
21. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs. 2008;22(3):213-237.
22. Lee J, Grizenko N, Bhat V, Sengupta S, Polotskaia A, Joober R. Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD. BMC Psychiatry. 2011;11:70.
23. Loo SK, Makeig S. Clinical utility of EEG in attention-deficit/hyperactivity disorder: a research update. Neurotherapeutics. 2012;9(3): 569-587.
24. Ogrim G, Kropotov J, Hestad K. The quantitative EEG theta/beta ratio in attention deficit/hyperactivity disorder and normal controls: sensitivity, specificity, and behavioral correlates. Psychiatry Res. 2012;198(3): 482-488.
25. Arns M, Gunkelman J, Breteler M, Spronk D. EEG phenotypes predict treatment outcome to stimulants in children with ADHD. J Integr Neurosci. 2008;7(3):421-438.
26. Liechti MD, Valko L, Müller UC, et al. Diagnostic value of resting electroencephalogram in attention-deficit/hyperactivity disorder across the lifespan. Brain Topogr. 2013;26(1):135-151.
27. Barry RJ, Clarke AR, Johnstone SJ. A review of electrophysiology in attention-deficit/hyperactivity disorder: I. Qualitative and quantitative electroencephalography. Clin Neurophysiol. 2003;114(2):171-183.
28. Clarke AR, Barry RJ, McCarthy R, Selikowitz M. EEG-defined subtypes of children with attention-deficit/hyperactivity disorder. Clin Neurophysiol. 2001;112(11):2098-2105.
29. Clarke AR, Barry RJ, McCarthy R, Selikowitz M. Excess beta activity in children with attention-deficit/hyperactivity disorder: an atypical electrophysiological group. Psychiatry Res. 2001;103(2-3):205-218.
30. Hajcak G, Weinberg A, MacNamara A, Foti D. ERPs and the study of emotion. In: Luck SJ, Kappenman ES, editors. The Oxford Handbook of Event-Related Potential Components. New York: Oxford University Press; 2012:441-473.
31. Falkenstein M, Hoormann J, Hohnsbein J. ERP components in Go/Nogo tasks and their relation to inhibition. Acta Psychol (Amst). 1999;101(2-3):267-291.
32. Brandeis D, Banaschewski T, Baving L, et al. Multicenter P300 brain mapping of impaired attention to cues in hyperactive children. J Am Acad Child Adolesc Psychiatry. 2002;41(8):990-998.
33. Wiersema JR, Roeyers H. ERP correlates of effortful control in children with varying levels of ADHD symptoms. J Abnorm Child Psychol. 2009;37(3):327-336.
34. Johnstone SJ, Barry RJ, Clarke AR. Ten years on: a follow-up review of ERP research in attention-deficit/hyperactivity disorder. Clin Neurophysiol. 2013;124(4):644-657.
35. van Rijn H, Kononowicz TW, Meck WH, Ng KK, Penney TB. Contingent negative variation and its relation to time estimation: a theoretical evaluation. Front Integr Neurosci. 2011;5:91.
36. Brunia CHM, van Boxtel GJM, Böcker KBE. Negative slow waves as indices of anticipation. In: Luck SJ, Kappermann ES, editors. The Oxford Handbook of Event-Related Potential Components. New York: Oxford University Press; 2012:189-208.
37. Ansari TL, Derakshan N. The neural correlates of cognitive effort in anxiety: effects on processing efficiency. Biol Psychol. 2011;86(3): 337-348.
38. Doehnert M, Brandeis D, Schneider G, Drechsler R, Steinhausen HC. A neurophysiological marker of impaired preparation in an 11-year follow-up study of attention-deficit/hyperactivity disorder (ADHD). J Child Psychol Psychiatry. 2013;54(3):260-270.
39. Linssen AM, Vuurman EF, Sambeth A, et al. Contingent negative variation as a dopaminergic biomarker: evidence from dose-related effects of methylphenidate. Psychopharmacology (Berl). 2011;218(3): 533-542.
40. Kappenman ES, Luck SJ. ERP components: the ups and downs of brainwave recordings. In: Luck SJ, Kappenman ES, editors. The Oxford Handbook of Event-Related Potential Components. New York: Oxford University Press; 2012:3-29.
41. Makeig S, Bell AJ, Jung T. Independent component analysis of electroencephalographic data. Adv Neural Inf Process Syst. 1996;8:145-151.
42. Kropotov JD, Ponomarev VA. Decomposing N2 nogo wave of event-related potentials into independent components. Neuroreport. 2009;20(18):1592-1596.
43. Olbrich HM, Maes H, Valerius G, Langosch JM, Feige B. Event-related potential correlates selectively reflect cognitive dysfunction in schizophrenics. J Neural Transm. 2005;112(2):283-295.
44. Kropotov JD, Ponomarev VA, Hollup S, Mueller A. Dissociating action inhibition, conflict monitoring and sensory mismatch into independent components of event related potentials in go/nogo task. Neuroimage. 2011;57(2):565-575.
45. Brunner JF, Hansen TI, Olsen A, Skandsen T, Håberg A, Kropotov J. Long-term test-retest reliability of the P3 nogo wave and two independent components decomposed from P3 NoGo wave in a visual go/nogo task. Int J Psychophysiol. Epub June 12, 2013.
46. Mueller A, Candrian G, Grane VA, Kropotov JD, Ponomarev VA, Baschera GM. Discriminating between ADHD adults and controls using independent ERP components and a support vector machine: a validation study. Nonlinear Biomed Phys. 2011;5:5
47. Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADSPL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36,980-988.
48. Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The development and well-being assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. J Child Psychol Psychiatry. 2000;41(5):645-655.
49. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257-268.
50. Gioia GA, Isquith PK. BRIEF: Behavior Rating Inventory of Executive Function. Lutz (FL): PAR; 2000.
51. Kropotov JD. Quantitative EEG Event-Related Potentials and Neurotherapy. Amsterdam: Elsevier; 2009.
52. van der Meere J. The role of attention. In: Sandberg S, editor. Hyperactivity Disorders of Childhood. Cambridge University Press; 1996:111-148.
53. Järveläinen L, Pauliina N. Event Related Brain Potential (ERP) Correlates of Activation and Effort in State Regulation among Children with Attentional Problems. Jyväskylä, Finland: University of Jyväskylä; 2000.
54. Sergeant J. The cognitive-energetic model: an empirical approach to attention-deficit hyperactivity disorder. Neurosci Biobehav Rev. 2000;24(1):7-12.
55. Toomey SL, Sox CM, Rusinak D, Finkelstein JA. Why do children with ADHD discontinue their medication? Clin Pediatr (Phila). 2012;51(8):763-769.